Xbrane Biopharma AB (publ) (STO:XBRANE)

Xbrane Biopharma AB Financials Overview

Financials in millions SEK. Fiscal year is January - December.

Revenue & Profits

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue Revenue Growth	83.3	152.35	148.1	238.73	57.62	10.71
Revenue Growth	-61.28%	2.87%	-37.96%	314.33%	438.03%	-
Gross Profit Gross Profit Growth	11.61	89.55	129.87	35.39	57.62	10.71
Operating Income Operating Income Growth	-58.07	-19.93	-82.34	-296.72	-152.65	-176.46
Net Income Net Income Growth	-75	127.24	-266.22	-388.17	-172.51	-188.38
Earnings Per Share EPS Growth	-3.95	7.74	-27.06	-1690.32	-843.34	-998.54
EPS Growth	-	-	-	-	-	-

Revenue by Geography

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023
Germany Germany Growth	82.7	67.5	66.5	209.9
India India Growth	-	84.3	54.1	-
Others Others Growth	0.5	0.6	1.1	-
North America North America Growth	-	-	26.4	28.7
Total Total Growth	83.4	152.4	148.1	238.6

Cash & Debt

Chart

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Investments Cash & Investments Growth	49.5	86.59	124.33	65.4	193.99	295.18
Total Debt Total Debt Growth	63.71	58.31	191.72	231.48	38.22	44.38
Net Cash (Debt) Net Cash Growth	-14.22	28.28	-67.39	-166.08	155.77	250.8
Net Cash Growth	-	-	-	-	-37.89%	5.88%
Net Cash Per Share Net Cash Per Share Growth	-0.69	1.72	-6.85	-723.19	761.51	1328.76

Cash Flow & CapEx

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Operating Cash Flow Operating Cash Flow Growth	-130.32	-250.69	-133.73	-406.68	-193.92	-219.61
Capital Expenditures CapEx Growth	-0.11	-	-0.5	-6.79	-11.62	-27.68
Free Cash Flow Free Cash Flow Growth	-130.42	-250.69	-134.23	-413.47	-205.53	-247.29
Free Cash Flow Growth	-	-	-	-	-	-

Margins

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Gross Margin	13.94%	58.77%	87.69%	14.82%	100.00%	100.00%
Operating Margin	-69.71%	-13.08%	-55.60%	-124.29%	-264.94%	-1647.75%
Pretax Margin	-88.73%	-28.84%	-87.59%	-134.89%	-292.46%	-1710.95%
Profit Margin	-90.04%	83.52%	-179.76%	-162.60%	-299.41%	-1759.04%
FCF Margin	-156.58%	-164.55%	-90.64%	-173.20%	-356.72%	-2309.16%

Valuation

Chart

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 2, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
PE Ratio	-	1.65	-	-	-	-
Forward PE	-	2.45	18.40	27.74	13.18	20.01
PS Ratio	2.37	1.38	1.66	1.25	39.19	245.04

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Sep 2, 2026

Data Sources Report a data error